OptimizeRx (OPRX) AI Stock Analysis

• Market Cap: $345.50M
• Dividend Yield: N/A
• Average Volume (3M): 404.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.07
• Revenue Growth: 25.90%
• EPS Growth: 46.13%
• Country: US
• Employees: 128
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.24
• Shares Outstanding: 18,565,033
• 10 Day Avg. Volume: 367,818
• 30 Day Avg. Volume: 404,344
• PEG Ratio: -0.65
• Price to Book (P/B): 0.76
• Price to Sales (P/S): 0.97
• P/FCF Ratio: 18.61
• Enterprise Value/Market Cap: 0.78
• Enterprise Value/Revenue: 2.85
• Enterprise Value/Gross Profit: 4.53
• Enterprise Value/Ebitda: -42.93
• 1Y Price Target: $20.70
• Price Target Upside: 9.99% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 68 Neutral
• Price Target: $18.50 ▼(-1.70% Downside)

OptimizeRx's strong earnings performance and positive technical indicators are offset by valuation concerns and profitability challenges. Recent corporate events and leadership changes are seen as positive strategic moves, contributing to a favorable outlook.

Positive Factors

Debt Management

Accelerated debt paydown is fueled by strong EBITDA performance.

Financial Performance

Investors reacted favorably to OptimizeRx's strong underlying growth momentum and revised guidance.

Market Position

The stock has been a year-to-date winner, with shares up 164%, indicating strong market performance.

Negative Factors

Revenue Guidance

Guidance implies a significant sequential decline in third-quarter revenue, which is not the typical seasonal pattern.

Revenue Surprise

From investors' perspective, the decision to exit the managed services part of the Medicx acquisition was an unforeseen top-line surprise.

OptimizeRx Business Overview & Revenue Model

Company Description

OptimizeRx (OPRX) is a healthcare technology company that operates in the digital health sector, focusing on improving patient outcomes through its innovative platform. The company provides a suite of solutions designed to enhance patient access to medications and streamline communication between healthcare providers, patients, and pharmaceutical companies. OptimizeRx's core products include electronic health record (EHR) integrations that facilitate the delivery of patient savings programs and medication information directly within the clinical workflow, thereby enhancing the prescribing process and adherence to treatment regimens.

How the Company Makes Money

OptimizeRx generates revenue primarily through its digital health platform, which offers services to pharmaceutical companies, healthcare providers, and payers. The company earns money by charging pharmaceutical manufacturers for access to its platform, where they can promote their patient support programs and discounts directly to healthcare providers. Additionally, OptimizeRx monetizes its EHR integrations by providing value-added services that enhance the functionality of electronic health records, driving user engagement and adoption. Partnerships with leading EHR vendors and collaborations with various healthcare stakeholders further contribute to its revenue streams by expanding its market reach and enhancing its service offerings.

OptimizeRx Financial Statement Overview

Summary

OptimizeRx shows positive revenue growth and strong cash flow trends, but faces profitability challenges with negative net income margins. The company's solid equity position and low leverage provide a stable foundation, yet operational inefficiencies need addressing.

Income Statement

OptimizeRx shows a positive revenue growth trend, with a TTM revenue increase of 2.43% compared to the previous year. However, the company is facing profitability challenges, as indicated by negative EBIT and net income margins. The gross profit margin remains strong at 62.97%, but the net profit margin is negative at -16.33%, reflecting ongoing operational inefficiencies.

Balance Sheet

The balance sheet reflects a solid equity position with a debt-to-equity ratio of 0.28, indicating low leverage. The equity ratio is robust at 69.28%, showing a strong capital structure. However, the company has experienced a decline in total assets, which may impact future growth potential.

Cash Flow

OptimizeRx demonstrates a positive trend in cash flow, with a significant increase in free cash flow by 32.12% in the TTM period. The operating cash flow to net income ratio is favorable, indicating efficient cash generation relative to net losses. However, the company needs to maintain this momentum to ensure long-term financial stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	94.36M	92.13M	71.52M	62.45M	61.29M	43.31M
Gross Profit	59.42M	59.38M	42.90M	38.97M	35.64M	24.11M
EBITDA	-6.27M	-8.90M	-21.31M	-9.42M	2.33M	646.89K
Net Income	-15.41M	-20.11M	-17.57M	-11.44M	378.08K	-2.21M
Balance Sheet
Total Assets	167.77M	171.17M	183.37M	134.65M	140.99M	60.33M
Cash, Cash Equivalents and Short-Term Investments	16.57M	13.38M	13.85M	74.14M	84.68M	10.52M
Total Debt	32.80M	33.19M	36.82M	234.43K	327.71K	448.75K
Total Liabilities	51.50M	54.17M	56.82M	8.54M	9.61M	10.35M
Stockholders Equity	116.27M	117.00M	126.55M	126.11M	131.38M	49.97M
Cash Flow
Free Cash Flow	6.31M	4.78M	-8.11M	10.41M	240.04K	-6.44M
Operating Cash Flow	6.63M	4.89M	-7.24M	10.65M	726.04K	-6.31M
Investing Cash Flow	-381.00K	-450.00K	-25.34M	-58.18M	-486.00K	-124.72K
Financing Cash Flow	-4.86M	-4.91M	28.22M	-18.95M	73.92M	-1.90M

OptimizeRx Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 18.82
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OPRX, the sentiment is Positive. The current price of 18.82 is above the 20-day moving average (MA) of 17.19, above the 50-day MA of 14.81, and above the 200-day MA of 9.50, indicating a bullish trend. The MACD of 1.06 indicates Negative momentum. The RSI at 65.66 is Neutral, neither overbought nor oversold. The STOCH value of 77.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OPRX.

OptimizeRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OPRX	68 Neutral	$345.50M	―	-8.21%	―	25.90%	46.13%
DH	52 Neutral	$571.35M	―	-64.27%	―	-5.24%	23.59%
Sector *	51 Neutral	$7.92B	-0.43	-41.67%	2.21%	22.29%	-1.85%
SOPH	51 Neutral	$230.45M	―	-74.09%	―	7.31%	-7.49%
AMWL	50 Neutral	$108.54M	―	-38.52%	―	5.83%	61.94%
HCAT	49 Neutral	$232.23M	―	-28.42%	―	5.55%	-0.99%
EUDA	―	$55.73M	―		―	―	―

OptimizeRx Corporate Events

OptimizeRx Announces Leadership Changes for Strategic Growth

On August 19, 2025, OptimizeRx Corporation announced leadership changes aimed at accelerating its strategic growth and achieving the Rule of 40 strategy, which balances sustained growth with increased profitability. Brendan Merrell was appointed as the Chief Operating Officer, while Edward Stelmakh transitioned to the role of Chief Financial & Strategic Officer to lead corporate strategy and financial operations. These changes reflect the company’s commitment to aligning talent and structure with its long-term strategic objectives under CEO Steve Silvestro’s management. The leadership advancements, including the promotion of Andy D’Silva to Chief Business Officer, are designed to enhance the company’s focus on profitable growth and shareholder value creation.

OptimizeRx CEO Steve Silvestro Joins Board of Directors

On June 24, 2025, OptimizeRx announced the appointment of its CEO, Steve Silvestro, to the Board of Directors, effective June 20, 2025. Silvestro, who became CEO in March 2025, is expected to enhance leadership and contribute to the company’s strategic initiatives aimed at value creation and strengthening its market position. The Board expressed confidence in Silvestro’s leadership, noting significant progress since he assumed the CEO role, and anticipates that his appointment will support the company’s growth and strategic direction.

OptimizeRx Stockholders Approve Key Governance Proposals

OptimizeRx held its 2025 Annual Meeting of Stockholders on June 11, 2025, where stockholders voted on three key proposals. The proposals included the election of five directors, approval of executive compensation, and ratification of UHY LLP as the independent accounting firm. All proposals were approved, impacting the company’s governance and financial oversight for the 2025 fiscal year.